{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:14:42Z","timestamp":1772057682169,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0200539","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T13:52:10Z","timestamp":1532008330000},"page":"e0200539","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-4273","authenticated-orcid":true,"given":"Paul","family":"Meyvisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrispin","family":"Kambili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Andries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nacer","family":"Lounis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Theeuwes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Dannemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Van der Elst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Molenberghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14737167.8.3.255","article-title":"Surrogate endpoints: Hopes and perils","volume":"8","author":"A Alonso","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2307\/2533853","article-title":"Criteria for the validation of surrogate endpoints in randomized experiments","volume":"54","author":"M Buyse","year":"1998","journal-title":"Biometrics"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"M Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA\u2019s accelerated approval process","volume":"24","author":"TR Fleming","year":"2005","journal-title":"Health Aff (Millwood)"},{"key":"ref5","first-page":"471","article-title":"Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report","volume":"114","year":"1976","journal-title":"Am Rev Respir Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0041-3879(81)90016-7","article-title":"Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. The results up to 30 months","volume":"62","year":"1981","journal-title":"Tubercle"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(10)70003-7","article-title":"Biomarkers for tuberculosis disease activity, cure, and relapse","volume":"10","author":"RS Wallis","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e63840","DOI":"10.1371\/journal.pone.0063840","article-title":"An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse","volume":"8","author":"PPJ Phillips","year":"2013","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tube.2010.03.007","article-title":"Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity","volume":"90","author":"GR Davies","year":"2010","journal-title":"Tuberculosis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12916-016-0565-y","article-title":"Limited role of culture conversion for decision making in individual patient care and for advancing novel regimens to confirmatory clinical trials","volume":"14","author":"PP Phillips","year":"2016","journal-title":"BMC Medicine"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/cid\/civ612","article-title":"Early biomarkers and regulatory innovation in multidrug-resistant tuberculosis","volume":"61","author":"RS Wallis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e0125403","DOI":"10.1371\/journal.pone.0125403","article-title":"Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update","volume":"10","author":"RS Wallis","year":"2015","journal-title":"PloS ONE"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e71116","DOI":"10.1371\/journal.pone.0071116","article-title":"Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model","volume":"8","author":"RS Wallis","year":"2013","journal-title":"PLoS ONE"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"M Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"MT Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-144-9-200605020-00008","article-title":"Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome","volume":"144","author":"TH Holtz","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"EV Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"key":"ref18","first-page":"607","article-title":"Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema","volume":"34","author":"MN Lassere","year":"2007","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"AH Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/biom.12483","article-title":"An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference","volume":"72","author":"A Alonso","year":"2016","journal-title":"Biometrics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"AH Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1164\/rccm.201704-0796LE","article-title":"Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens","volume":"196","author":"AH Diacon","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1201\/b11826","article-title":"Flexible imputation of missing data","author":"S. van Buuren","year":"2012"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/sim.7197","article-title":"Assessing a surrogate predictive value: A causal inference approach","volume":"36","author":"A Alonso","year":"2017","journal-title":"Stat Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"G Heinze","year":"2002","journal-title":"Stat Med"},{"key":"ref26","unstructured":"Van der Elst W, Meyvisch P, Alonso A. Evaluation of surrogate endpoints in clinical trials. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cran.r-project.org\/web\/packages\/Surrogate\" xlink:type=\"simple\">https:\/\/cran.r-project.org\/web\/packages\/Surrogate<\/ext-link> (accessed: June 13, 2017)."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"AS Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"ref28","unstructured":"World Health Organization. Treatment of tuberculosis: guidelines. 4th Edn (WHO\/HTM\/TB\/2009.420). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aidsdatahub.org\/dmdocuments\/Treatment_of_TB_Guidelines.pdf\" xlink:type=\"simple\">www.aidsdatahub.org\/dmdocuments\/Treatment_of_TB_Guidelines.pdf<\/ext-link> (last accessed: November 23, 2017)."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/jac\/dkx317","article-title":"Modelling of mycobacterial load reveals bedaquiline&apos;s exposure-response relationship in patients with drug-resistant TB","volume":"72","author":"EM Svensson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref30","unstructured":"World Health Organization. Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients. May 12 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/news\/releases\/2016\/multidrug-resistant-tuberculosis\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/mediacentre\/news\/releases\/2016\/multidrug-resistant-tuberculosis\/en\/<\/ext-link> (last accessed: November 23, 2017)."},{"key":"ref31","unstructured":"Conradie F, Diacon AH, Everitt D, Mendel C, van Nieckerk C, Howell P, et al. The NIX-TB trial of pretomanid, bedaquiline and linezolid to treat XDR-TB. Presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), CROI Foundation in partnership with the International Antiviral Society-USA, Seattle, WA, February 13\u201316, 2017. Abstract 80LB."},{"key":"ref32","unstructured":"Dawson R, Harris K, Conradie A, Burger D, Murray S, Mendel C, et al. Efficacy of bedaquiline, pretomanid, moxifloxacin &amp; PZA (BPaMZ) against DS- &amp; MDR-TB. Presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), CROI Foundation in partnership with the International Antiviral Society-USA, Seattle, WA, February 13\u201316, 2017. Abstract 724LB."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0200539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T21:20:07Z","timestamp":1571606407000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0200539"}},"subtitle":[],"editor":[{"given":"Alejandro","family":"Escobar-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0200539","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}